<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00351143</url>
  </required_header>
  <id_info>
    <org_study_id>ACE104325</org_study_id>
    <nct_id>NCT00351143</nct_id>
  </id_info>
  <brief_title>A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control</brief_title>
  <official_title>A Randomized, Open Label Comparative Study to Determine the Proportion of Asthma Patients on SERETIDE Diskus 50/250 mcg b.i.d. Achieving Total Control When Given Medication and Compliance Enhancement Training Compared to Those Receiving Medication Only</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate whether study subjects with previously uncontrolled asthma
      treated with SERETIDE Diskus 50/250 CCI18781+GR33343 mcg twice a day can attain a level of
      Total Control of their condition and whether adherence to treatment can be enhanced by
      teaching the subjects. Two groups of equal size with identical medical treatment will be
      compared with each other, the test group receiving three training modules during study visits
      and the control group regular study visits only.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2005</start_date>
  <completion_date type="Actual">June 13, 2007</completion_date>
  <primary_completion_date type="Actual">June 13, 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of subjects who achieved Total asthma Control: Period 2</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Proportion of subjects who achieved Total Control in 7 out of the last 8 consecutive weeks in treatment period 2 with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing and compliance enhancement training compared with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing without compliance enhancement training.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who achieved Total Control with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing: Period 2</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Proportion of subjects who achieved Total Control with salmeterol/fluticasone propionate 50/250 g b.i.d. fixed dosing in treatment period 1 will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first individual week with Total Control</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Time to first individual week with Total Control in treatment period 2 will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning peak expiratory flow (PEF)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>PEF is defined as a person's maximum speed of expiration and will be measured using a peak flow meter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>FEV1 is defined as Forced Expiratory Volume in the first second. The volume of air that can be forced out in one second after taking a deep breath, an important measure of pulmonary function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma symptom score</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Asthma symptom score will be analyzed to check the symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects using rescue medication</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Rescue medication usage will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of nights with awakening due to asthma</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Number of nights with awakening due to asthma will be analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma severity score</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Asthma severity score will be analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs)</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Adverse events will be observed and counted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AQLQ score</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Quality of life of subjects with asthma will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">274</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Interventional group: Period 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group: Period 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving salmeterol/fluticasone propionate: Period 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training</intervention_name>
    <description>Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.</description>
    <arm_group_label>Interventional group: Period 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salmeterol/fluticasone propionate 50/250 µg</intervention_name>
    <description>Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2</description>
    <arm_group_label>Subjects receiving salmeterol/fluticasone propionate: Period 1</arm_group_label>
    <arm_group_label>Control group: Period 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosed with persistent asthma.

          -  Not treated with the combination of a ICS (inhaled corticosteroid)and a LABA
             (long-acting beta-agonist).

          -  Female subjects must not be fertile or must use effective contraception.

          -  Subject must be able to comply with the use of the questionnaires in the local
             language.

        Exclusion criteria:

          -  Known or suspected Chronic Obstructive Pulmonary Disease.

          -  Pregnant or lactating.

          -  Participating investigator, employee of an investigator, or family member of any of
             the aforementioned.

          -  Smoking history: Pack-years &gt; 10 years.

          -  Have known clinical or laboratory evidence of a serious uncontrolled systemic disease.

          -  Known hypersensitivity to any substance contained in investigational product or
             as-needed medication.

          -  Treatment with oral corticosteroid within 2 months prior to the screening visit.

          -  Upper or lower respiratory tract infection (microbiologically verified) within 1 month
             prior to screening visit.

          -  Acute asthma exacerbation requiring hospitalisation or emergency room treatment within
             3 months prior to the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <zip>DK-8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kobenhavn NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarau</city>
        <zip>5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Allschwil</city>
        <zip>4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>4001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>4053</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>4054</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Basel</city>
        <zip>4058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bever</city>
        <zip>7502</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brittnau</city>
        <zip>4805</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castione</city>
        <zip>6532</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Düdingen</city>
        <zip>3186</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Egg</city>
        <zip>8132</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Faltigberg-Wald</city>
        <zip>8639</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Horw</city>
        <zip>6048</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Klosters</city>
        <zip>7250</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malvaglia</city>
        <zip>6713</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Massagno</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pregassona</city>
        <zip>6963</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Steckborn</city>
        <zip>8266</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wald</city>
        <zip>8636</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wigoltingen</city>
        <zip>8556</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worb</city>
        <zip>3076</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2006</study_first_submitted>
  <study_first_submitted_qc>July 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2006</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QoL</keyword>
  <keyword>Asthma</keyword>
  <keyword>asthma compliance enhancement</keyword>
  <keyword>Salmeterol/fluticasone</keyword>
  <keyword>Total control</keyword>
  <keyword>SERETIDE</keyword>
  <keyword>FEV1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

